(Q30375975)

21 June 2017

1 reference

title

Current status and progress of prepandemic and pandemic influenza vaccine development. (English)

1 reference

21 June 2017

0 references

1 reference

0 references

2

Geert Leroux-Roels

0 references

author name string

Isabel Leroux-Roels

series ordinal

1

1 reference

21 June 2017

publication date

1 April 2009

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

401-423

1 reference

Containing pandemic influenza at the source.

21 June 2017

cites work

1 reference

Strategies for containing an emerging influenza pandemic in Southeast Asia

21 January 2018

1 reference

Strategies for mitigating an influenza pandemic

21 January 2018

1 reference

Modeling targeted layered containment of an influenza pandemic in the United States.

21 January 2018

1 reference

H5N1 influenza--continuing evolution and spread

21 January 2018

1 reference

Scientific barriers to developing vaccines against avian influenza viruses.

21 January 2018

1 reference

Selection of influenza vaccine strains and developing pandemic vaccines.

21 January 2018

1 reference

Experience with the clinical development of influenza vaccines for potential pandemics.

21 January 2018

1 reference

Development of effective vaccines against pandemic influenza.

21 January 2018

1 reference

H5N1 vaccines: how prepared are we for a pandemic?

21 January 2018

1 reference

Vaccine development for an imminent pandemic: why we should worry, what we must do.

21 January 2018

1 reference

Avian and pandemic influenza: an overview.

21 January 2018

1 reference

Pandemic H5N1 influenza vaccine development: an update.

21 January 2018

1 reference

H5N1 viruses and vaccines

21 January 2018

1 reference

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

21 January 2018

1 reference

Human infection with highly pathogenic H5N1 influenza virus.

21 January 2018

1 reference

Avian influenza virus (H5N1): a threat to human health.

21 January 2018

1 reference

From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

21 January 2018

1 reference

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

21 January 2018

1 reference

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

21 January 2018

1 reference

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

21 January 2018

1 reference

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

21 January 2018

1 reference

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

21 January 2018

1 reference

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

21 January 2018

1 reference

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

21 January 2018

1 reference

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

21 January 2018

1 reference

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

Pathogenesis of avian influenza A (H5N1) viruses in ferrets

21 January 2018

1 reference

Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.

21 January 2018

1 reference

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

21 January 2018

1 reference

Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.

21 January 2018

1 reference

Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly

21 January 2018

1 reference

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

21 January 2018

1 reference

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.

21 January 2018

1 reference

Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

21 January 2018

1 reference

Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children.

21 January 2018

1 reference

Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement

21 January 2018

1 reference

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

21 January 2018

1 reference

Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori

21 January 2018

1 reference

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

Pre- or post-pandemic influenza vaccine?

21 January 2018

1 reference

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.15

1 reference

release_whlfdipvl5d67cjhiimqdutqye

21 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/whlfdipvl5d67cjhiimqdutqye

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference